Insulet EBITDA Margin 2010-2025 | PODD
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Insulet (PODD) over the last 10 years. The current EBITDA margin for Insulet as of June 30, 2025 is .
| Insulet EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-06-30 | $2.36B | $0.49B | 20.93% |
| 2025-03-31 | $2.20B | $0.43B | 19.32% |
| 2024-12-31 | $2.07B | $0.39B | 18.81% |
| 2024-09-30 | $1.99B | $0.38B | 19.35% |
| 2024-06-30 | $1.87B | $0.35B | 18.62% |
| 2024-03-31 | $1.78B | $0.32B | 18.18% |
| 2023-12-31 | $1.70B | $0.29B | 17.26% |
| 2023-09-30 | $1.56B | $0.21B | 13.35% |
| 2023-06-30 | $1.47B | $0.15B | 10.44% |
| 2023-03-31 | $1.37B | $0.09B | 6.80% |
| 2022-12-31 | $1.31B | $0.10B | 7.74% |
| 2022-09-30 | $1.24B | $0.13B | 10.14% |
| 2022-06-30 | $1.18B | $0.16B | 13.16% |
| 2022-03-31 | $1.14B | $0.21B | 18.21% |
| 2021-12-31 | $1.10B | $0.18B | 16.74% |
| 2021-09-30 | $1.04B | $0.14B | 13.21% |
| 2021-06-30 | $1.00B | $0.12B | 12.46% |
| 2021-03-31 | $0.96B | $0.12B | 12.42% |
| 2020-12-31 | $0.90B | $0.11B | 11.73% |
| 2020-09-30 | $0.87B | $0.12B | 13.26% |
| 2020-06-30 | $0.83B | $0.11B | 12.73% |
| 2020-03-31 | $0.78B | $0.08B | 10.57% |
| 2019-12-31 | $0.74B | $0.08B | 10.57% |
| 2019-09-30 | $0.69B | $0.07B | 10.37% |
| 2019-06-30 | $0.65B | $0.06B | 8.88% |
| 2019-03-31 | $0.60B | $0.05B | 8.67% |
| 2018-12-31 | $0.56B | $0.04B | 7.80% |
| 2018-09-30 | $0.53B | $0.03B | 4.91% |
| 2018-06-30 | $0.50B | $0.02B | 4.19% |
| 2018-03-31 | $0.49B | $0.01B | 2.67% |
| 2017-12-31 | $0.47B | $0.01B | 1.51% |
| 2017-09-30 | $0.44B | $0.00B | 0.68% |
| 2017-06-30 | $0.41B | $0.00B | 0.73% |
| 2017-03-31 | $0.39B | $0.01B | 1.29% |
| 2016-12-31 | $0.37B | $0.00B | 0.82% |
| 2016-09-30 | $0.35B | $0.00B | -1.15% |
| 2016-06-30 | $0.32B | $-0.02B | -6.50% |
| 2016-03-31 | $0.30B | $-0.03B | -11.11% |
| 2015-12-31 | $0.26B | $-0.03B | -12.50% |
| 2015-09-30 | $0.20B | $-0.02B | -10.77% |
| 2015-06-30 | $0.20B | $-0.01B | -5.03% |
| 2015-03-31 | $0.21B | $0.00B | -0.95% |
| 2014-12-31 | $0.23B | $0.00B | 1.30% |
| 2014-09-30 | $0.29B | $0.00B | 0.70% |
| 2014-06-30 | $0.27B | $-0.01B | -4.43% |
| 2014-03-31 | $0.26B | $-0.01B | -5.02% |
| 2013-12-31 | $0.25B | $-0.02B | -6.88% |
| 2013-09-30 | $0.24B | $-0.02B | -9.75% |
| 2013-06-30 | $0.23B | $-0.02B | -6.52% |
| 2013-03-31 | $0.22B | $-0.02B | -9.05% |
| 2012-12-31 | $0.21B | $-0.03B | -11.79% |
| 2012-09-30 | $0.20B | $-0.03B | -14.93% |
| 2012-06-30 | $0.19B | $-0.03B | -16.23% |
| 2012-03-31 | $0.17B | $-0.04B | -20.93% |
| 2011-12-31 | $0.15B | $-0.03B | -22.37% |
| 2011-09-30 | $0.13B | $-0.04B | -30.08% |
| 2011-06-30 | $0.11B | $-0.04B | -33.63% |
| 2011-03-31 | $0.10B | $-0.03B | -30.77% |
| 2010-12-31 | $0.10B | $-0.03B | -35.05% |
| 2010-09-30 | $0.09B | $-0.03B | -32.58% |
| 2010-06-30 | $0.08B | $-0.04B | -42.17% |
| 2010-03-31 | $0.08B | $-0.04B | -54.67% |
| 2009-12-31 | $0.07B | $-0.05B | -72.73% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $23.536B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.801B | 26.83 |
| Boston Scientific (BSX) | United States | $156.873B | 37.41 |
| Stryker (SYK) | United States | $150.304B | 30.59 |
| EssilorLuxottica (ESLOY) | France | $143.779B | 0.00 |
| Medtronic (MDT) | Ireland | $118.071B | 16.65 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.982B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.547B | 24.90 |
| ResMed (RMD) | United States | $41.283B | 29.52 |
| GE HealthCare Technologies (GEHC) | United States | $33.904B | 15.94 |
| Agilent Technologies (A) | United States | $33.716B | 21.78 |
| Terumo (TRUMY) | Japan | $26.887B | 31.86 |
| Koninklijke Philips (PHG) | Netherlands | $26.663B | 17.64 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.155B | 13.47 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.315B | 0.00 |
| Baxter (BAX) | United States | $12.599B | 9.73 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.925B | 29.11 |
| Lantheus Holdings (LNTH) | United States | $3.865B | 10.45 |
| Envista Holdings (NVST) | United States | $3.530B | 24.70 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.295B | 14.62 |
| Perrigo (PRGO) | Ireland | $3.287B | 8.21 |
| ICU Medical (ICUI) | United States | $3.126B | 21.28 |
| Haemonetics (HAE) | United States | $2.651B | 11.83 |
| LeMaitre Vascular (LMAT) | United States | $2.166B | 46.45 |
| Curaleaf Holdings (CURLF) | Canada | $2.148B | 0.00 |
| Acuren (TIC) | United States | $2.126B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.886B | 11.87 |
| Green Thumb Industries (GTBIF) | United States | $1.876B | 80.57 |
| AtriCure (ATRC) | United States | $1.854B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.508B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.305B | 15.41 |
| Neogen (NEOG) | United States | $1.247B | 19.79 |
| AdaptHealth (AHCO) | United States | $1.246B | 17.71 |
| BioLife Solutions (BLFS) | United States | $1.218B | 2543.00 |
| InMode (INMD) | Israel | $0.960B | 8.88 |
| Kestra Medical Technologies (KMTS) | United States | $0.924B | 0.00 |
| Valneva SE (VALN) | France | $0.745B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.699B | 0.00 |
| SNDL (SNDL) | Canada | $0.665B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.611B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.595B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.62 |
| Evolus (EOLS) | United States | $0.490B | 0.00 |
| Surmodics (SRDX) | United States | $0.488B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.475B | 16.36 |
| CeriBell (CBLL) | United States | $0.425B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.380B | 0.00 |
| Owens & Minor (OMI) | United States | $0.378B | 3.35 |
| Canopy Growth (CGC) | Canada | $0.362B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.340B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.302B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.301B | 0.00 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Omeros (OMER) | United States | $0.289B | 0.00 |
| Brainsway (BWAY) | Israel | $0.288B | 58.69 |
| Capricor Therapeutics (CAPR) | United States | $0.286B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.278B | 21.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.254B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.244B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Organigram Global (OGI) | Canada | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.214B | 0.00 |
| Exagen (XGN) | United States | $0.210B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.196B | 16.34 |
| FitLife Brands (FTLF) | United States | $0.176B | 21.66 |
| Biote (BTMD) | United States | $0.166B | 5.51 |
| Jushi Holdings (JUSHF) | United States | $0.147B | 0.00 |
| Jin Medical (ZJYL) | China | $0.128B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.115B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.66 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.058B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.10 |
| Zynex (ZYXI) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.051B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.75 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.45 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Sharps Technology (STSS) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |